This study aims to investigate the expression of thioredoxin 1, peroxiredoxin 1 and peroxiredoxin 2 in bulky cervical squamous carcinoma and its predictive role in cisplatin-based neoadjuvant chemotherapy
2019
Expression of thioredoxin 1 and peroxiredoxins in squamous cervical carcinoma and its predictive role in NACT
Key concepts
Scholarcy highlights
- This study aims to investigate the expression of thioredoxin 1, peroxiredoxin 1 and peroxiredoxin 2 in bulky cervical squamous carcinoma and its predictive role in cisplatin-based neoadjuvant chemotherapy
- Thioredoxin 1, peroxiredoxin 1/ 2 are overexpressed in cervical squamous cancer
- The aim of the current study is to determine the expression of thioredoxin 1, Prx 1 and Prx 2 in squamous cervical carcinoma and their potential roles in predicting chemoresistance among stage IB2 or IIA2 squamous cervical cancer patients treated with neoadjuvant chemotherapy
- Our results demonstrated that the higher expression of Trx 1, Prx 1 and Prx 2 in prechemotherapy could predict a poor response to Neoadjuvant chemotherapy in cervical squamous cancer
- Measuring Trx 1, Prx 1 and Prx 2 in biopsy samples before treatment may contribute to more effective management of bulky cervical cancer
- There were no significant differences in patients or tumor characteristics between the responder and non-responder cohorts
- More studies with large samples are needed to determine the predictive role of Trx 1, Prx 1 and Prx 2 in cervical cancer chemotherapy
Need more features? Save interactive summary cards to your Scholarcy Library.